Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group

被引:208
作者
Schiller, JH
Adak, S
Cella, D
DeVore, RF
Johnson, DH
机构
[1] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Evanston Northwestern Healthcare, Evanston, IL USA
[4] Northwestern Univ, Evanston, IL USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
关键词
D O I
10.1200/JCO.2001.19.8.2114
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the efficacy of topotecan in combination with standard chemotherapy in previously untreated patients with extensive-stage small-cell lung cancer (SCLC), the Eastern Cooperative Oncology Group (ECOG) conducted a phase III trial. Patients and Methods: Eligible patients had measurable or assessable disease and an ECOG performance status of 0 to 2; stable brain metastases were allowed. All patients received four cycles of cisplatin and etoposide every 3 weeks (step 1; PE). Patients with stable or responding disease were then randomized to observation or four cycles of topatecan (1.5 mg/m(2)/d for 5 days, every 3 weeks; step 2). A total of 402 eligible patients were registered to step 1, and 223 eligible patients were registered to step 2 (observation, n = 111; topatecan, n = 112). Results: Complete and partial response rates to induction PE were 3% and 32%, respectively. A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%). The median survival time for all 402 eligible patients was 9.6 months. Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P < .001). However, overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P = .43), Grade 4 neutropenia and thrombocytapenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2, Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients, Grade 3/4 anemia developed in 22% of patients who received topotecan. No difference in quality of life between topatecan and observation was observed at any assessment time or for any of the subscale scores. Conclusion: Four cycles of PE induction therapy followed by four cycles of topatecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC, Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status. <(c)> 2001 by American Society of Clinical Oncology.
引用
收藏
页码:2114 / 2122
页数:9
相关论文
共 31 条
[1]  
ANZI H, 1992, P AN M AM SOC CLIN, V33, P431
[2]  
ARDIZZONI A, 1996, ANN ONCOL, V7, P106
[3]   SEQUENTIAL ADMINISTRATION OF CAMPTOTHECIN AND ETOPOSIDE CIRCUMVENTS THE ANTAGONISTIC CYTOTOXICITY OF SIMULTANEOUS DRUG ADMINISTRATION IN SLOWLY GROWING HUMAN COLON-CARCINOMA HT-29 CELLS [J].
BERTRAND, R ;
OCONNOR, PM ;
KERRIGAN, D ;
POMMIER, Y .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :743-748
[4]  
Blaney SM, 1996, CANCER-AM CANCER SOC, V78, P527
[5]  
BLANEY SM, 1993, CANCER RES, V53, P1032
[6]   The significance of the sequence of administration of topotecan and etoposide [J].
Bonner, JA ;
Kozelsky, TF .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 39 (1-2) :109-112
[7]   RELIABILITY AND VALIDITY OF THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY - LUNG (FACT-L) QUALITY-OF-LIFE INSTRUMENT [J].
CELLA, DF ;
BONOMI, AE ;
LLOYD, SR ;
TULSKY, DS ;
KAPLAN, E ;
BONOMI, P .
LUNG CANCER, 1995, 12 (03) :199-220
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]  
Eckardt J, 1996, ANN ONCOL, V7, P107
[10]   CISPLATIN PLUS ETOPOSIDE CONSOLIDATION FOLLOWING CYCLOPHOSPHAMIDE, DOXORUBICIN, AND VINCRISTINE IN LIMITED SMALL-CELL LUNG-CANCER [J].
EINHORN, LH ;
CRAWFORD, J ;
BIRCH, R ;
OMURA, G ;
JOHNSON, DH ;
GRECO, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) :451-456